MicroRNA-29a Is a Candidate Biomarker for Alzheimer's Disease in Cell-Free Cerebrospinal Fluid
Publication year
2016Source
Molecular Neurobiology, 53, 5, (2016), pp. 2894-9ISSN
Publication type
Article / Letter to editor
Display more detailsDisplay less details
Organization
Geriatrics
Neurology
Laboratory Medicine
Journal title
Molecular Neurobiology
Volume
vol. 53
Issue
iss. 5
Page start
p. 2894
Page end
p. 9
Subject
Radboudumc 1: Alzheimer`s disease DCMN: Donders Center for Medical Neuroscience; Radboudumc 3: Disorders of movement DCMN: Donders Center for Medical NeuroscienceAbstract
The identification of reliable biomarkers for Alzheimer's disease (AD) remains challenging. Recently, abnormal levels of microRNAs (miRNAs) miR-27a, miR-29a, miR-29b, and miR-125b in cerebrospinal fluid (CSF) of AD patients were reported. We aimed to confirm the biomarker potential of these miRNAs for AD diagnosis. Additionally, we examined the influence of blood contamination on CSF miRNA levels as potential confounding factor. We studied expression levels of the four miRNAs by quantitative PCR in CSF samples of AD patients and non-demented controls, and in blood-spiked CSF. Levels of miR-29a, but not of the other three miRNAs, were increased by a factor of 2.2 in CSF of AD patients. Spiking of small amounts of blood into CSF revealed that miR-27a and miR-29a, but not miR-125b levels were strongly influenced by the number of blood cells in the sample. In conclusion, miR-29a may be a candidate biomarker for AD, but only when used in cell-free CSF.
This item appears in the following Collection(s)
- Academic publications [246438]
- Electronic publications [134074]
- Faculty of Medical Sciences [93307]
- Open Access publications [107627]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.